10 billion real to be invested in Brazil’s production of biotech drugs by 2016

27 January 2014

Brazil's Development Bank (BNDS) plans to invest up to 10 billion real ($4.2 billion) in the production of biotech drugs by 2016, writes Juliane Carvalho on Brazil Pharma News, quoting an article published by Brasil Economico.

This large size of the investments demonstrates the near future projections for pharmaceutical market growth, newer investment opportunities and the increased number of consumers in Brazil.

Between 2011 and 2013 the amount of investments carried out by BNDS in the pharmaceutical and medical devices sectors increased by 275%. BNDS executives also shared the fact that chronic and degenerative diseases affect a every growing number of the Brazilian population with higher life expectancy. The epidemiological data allied with the fact there isn't a large scale commercial production of biotech drugs and their near patent expiry have generated much interest by the national industry and its investors.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK